ENTITY
CanSino Biologics

CanSino Biologics (6185 HK)

236
Analysis
Health Care • China
CanSino Biologics is a biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of innovative vaccine products for human use, primarily focusing on infectious diseases. Its product portfolio includes vaccines for meningitis, pneumonia, pertussis, diphtheria, tetanus, COVID-19, tuberculosis, shingles, and Ebola virus disease. The company was founded in 2009 and is headquartered in Tianjin, China.
more
Exchange Announcement • 14 Oct 2026 16:30

Notice Of Board Meeting

Exchange Announcement • 17 Sep 2026 16:30

2026 Interim Report

Exchange Announcement • 16 Sep 2026 17:47

Announcement On The Grant Of Reserved Restricted Shares Under The 2025 A Share Incentive Scheme

Exchange Announcement • 27 Aug 2026 19:14

Interim Results Announcement For The Six Months Ended June 30, 2026

Exchange Announcement • 26 Aug 2026 18:16

Voluntary Announcement - Update On Mrna Technology Platform Development

x